There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...

Considering the reasons behind the jump in licensing deal values, Chan added: “Licensing agreement deal values for mRNA-based ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

FDA's approval of Astellas' therapy for gastric cancer, and CVS Health's leadership shuffle as Karen Lynch steps down amid ...

This week, we visit with Katie Lessel Young, a pharmacy resident with Monument Health.

The XEC variant of Covid is quickly becoming the dominant strain of the winter, but the current vaccines may not be as ...

Even previous versions of the vaccine built from XEC’s predecessors like omicron might not be as effective against the new ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

The mRNA Revolution When the COVID-19 pandemic struck, the world's medical community initially prepared for a disaster of the scale of the Spanish Flu, which struck during WW1 and killed 50 million ...

A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...

Vaccination for influenza, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and respiratory syncytial virus (RSV ...